Sanofi Signs Deal with Principia to Strengthen its Position in Multiple Sclerosis
By Natasha Piper
Pharma Deals Review: Vol 2017 Issue 11 (Table of Contents)
Published: 22 Nov-2017
DOI: 10.3833/pdr.v2017.i11.2286 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Sanofi has promised up to US$805 M to Principia Biopharma in return for licensing global rights to a Phase I drug that has potential in the treatment of multiple sclerosis (MS) and other neurological disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS